Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 49 - 60 of 430
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: Alpha-1 antitrypsin deficiency: A poster child for nucleic acid therapy

ERN Rare-Liver on-demand Webinar: Alpha-1 antitrypsin deficiency: A poster child for nucleic acid therapy

On-demand Webinars
View
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: Portal hypertension (CPSH) in Wilson Disease

ERN Rare-Liver on-demand Webinar: Portal hypertension (CPSH) in Wilson Disease

On-demand Webinars
View

EASL Studio S2 E14: Elastography – The new non-invasive gold standard in portal hypertension?

Description

Compensated advanced chronic liver disease (cALD) refers to a spectrum of advanced liver fibrosis and cirrhosis in asymptomatic patients. Elastography, which measure liver stiffness has been recommended as non-invasive diagnostic method.

  • What are the limitations when using liver stiffness measurements for diagnosis?
  • What role can blood-based serum markers play?
  • Should the measurement cut offs be reviewed for different patient populations?

This EASL studio is supported by Boehringer Ingelheim and Siemens Healthineers. EASL has received no input from Boehringer Ingelheim and Siemens Healthineers with regards to the content of this programme.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Related episode:

S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?

 

Moderator

  
Thomas REIBERGER

Thomas Reiberger is a hepatologist at the Medical University of Vienna focusing on translational research in the field of advanced chronic liver disease. His Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis deciphers molecular mechanisms involved in fibrogenesis and fibrosis regression and evaluates novel treatment options for portal hypertension and antifibrotic therapies in preclinical studies. As a physician, he heads the liver outpatient clinic, the Ultrasound/Elastography unit and the post liver transplant care at the Medical University of Vienna. Currently, he also serves as the Scientific Secretary of the Baveno Cooperation.

Faculty

  
Maja Thiele Maja Thiele is Professor of Hepatology at Department of Gastroenterology and Hepatology, Odense University Hospital and University of Southern Denmark. She works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research focuses on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection and cost-effective referral pathways. Maja Thiele was an elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, and AASLD clinical guidance. She has also been a partner in the European research consortia GALAXY, LiverScreen, MicrobPredict and SALVE.
Manolis Tsochatzis

Emmanuel Tsochatzis is a Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health in the Royal Free Hospital, London, UK and Head of the Centre for Metabolic Liver Diseases. His clinical and research interests include NAFLD, cirrhosis and portal hypertension and non-invasive fibrosis assessment. He is a member of the EASL scientific committee and Governing Board since 2019. He has led several international research collaborations resulting in more than 260 publications in peer reviewed journals. He has received funding for his research from NIHR, EASL and EU Horizon 2020.
Log in to post comments
Liver Tumours
Quiz: A 45-years-old female diagnosed with primary sclerosing cholangitis (PSC) and no history of liver cirrhosis or inflammatory bowel disease (IBD)

Quiz: A 45-years-old female diagnosed with primary sclerosing cholangitis (PSC) and no history of liver cirrhosis or inflamma...

Quiz
View

EASL Studio S5 E15: EASL Studio’s holiday reflection: A look back to leap forward

Description

Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health.

Faculty

  • Aleksander Krag (Moderator)
  • Thomas Berg (Faculty)
  • Ahmed Elsharkawy (Faculty)
  • Debbie Shawcross (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off
General Hepatology
EASL Studio Podcast S5 E15: EASL Studio’s holiday reflection: A look back to leap forward

EASL Studio Podcast S5 E15: EASL Studio’s holiday reflection: A look back to leap forward

Podcasts
View
General Hepatology

EASL Studio: The bumpy road of Hepatitis B drug development successes and challenges

EASL Studio
View
General Hepatology

EASL Studio: Clinical trials in rare diseases – opportunities and challenges

EASL Studio
View
General Hepatology

EASL Studio: What does the future look like for patients with NAFLD?

EASL Studio
View
General Hepatology

EASL Studio:Liver cirrhosis in 2023: unmet needs and how to address them? (Complete Session)

EASL Studio
View
General Hepatology

EASL Studio: The battle to reduce alcohol harms… EASL’s new policy

EASL Studio
View
General Hepatology

EASL Studio Opening

EASL Studio
View
Displaying 49 - 60 of 430